ResMed Inc.
$235.63-$1.25 (-0.5%)
Last close · Data as of Nov 20, 2026
- Market cap
- $28.2B
- P/E
- 20.1x
- EV / EBITDA
- 14.5x
- Revenue
- $5.1B
- Net margin
- 27.2%
- ROCE
- 23.6%
Price chart
Technical chartScreen technicals →-3.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -4.0%
- 3M
- +3.1%
- 6M
- +12.3%
- 1Y
- -3.4%
- 5Y
- -9.5%
52-week range
Day change -$1.25 (-0.5%) from $237 to $236 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in RMD, bought on each weekday since 2021.
News & filings
What ResMed filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthOperating profit was 36.9 times interest costs.
Concerns
No concern stands out for this company on the data on file.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software.
Read moreShow less
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Shares outstanding
- 146.4M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $28.2B
- P/E
- 20.1x
- P/B
- 4.7x
- EV / EBITDA
- 14.5x
- EV / Sales
- 5.4x
- P/S
- 5.5x
- 52-week high
- $275.96
- 52-week low
- $182.82
Profitability
- Operating margin
- 32.8%
- Net margin
- 27.2%
- EBITDA margin
- 37.4%
- ROE
- 23.5%
- ROCE
- 23.6%
- ROA
- 17.1%
- Asset turnover
- 0.63
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $5.1B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 9.8%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 12.9%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 37.2%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $1.7B
Solvency
- Current ratio
- 3.44
- Debt / Equity
- 0.14
- Debt / Assets
- 0.10
- CFO / Net profit
- 1.25
- Cash / Market cap
- 4.3%
Where the revenue went
Of every $100 of FY2025 revenue, $27 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $2.1B |
| Revenue | Gross profit | $3.1B |
| Gross profit | Research and development | $331.3M |
| Gross profit | Selling, general and administrative | $991.0M |
| Gross profit | Other operating expenses | $45.3M |
| Gross profit | Operating income | $1.7B |
| Operating income | Pretax income | $1.7B |
| Operating income | Interest and other expense | $9.8M |
| Pretax income | Tax and other | $276.8M |
| Pretax income | Net income | $1.4B |
Revenue and net profit
Revenue grew 9.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $3.6B | $779.4M |
| FY2023 | $4.2B | $897.6M |
| FY2024 | $4.7B | $1.0B |
| FY2025 | $5.1B | $1.4B |
Cash flows
FY2025: $1.8B from operations, $1.7B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $351.1M | $195.1M |
| FY2023 | $693.3M | $559.3M |
| FY2024 | $1.4B | $1.3B |
| FY2025 | $1.8B | $1.7B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $5.1B+9.8%1Y
- EBITDA
- $1.9B+20.2%1Y
- Net profit
- $1.4B+37.2%1Y
- Cash from operations
- $1.8B+25.0%1Y
- Free cash flow
- $1.7B+28.3%1Y
- Revenue CAGR, 3Y
- 12.9%
- Net profit CAGR, 3Y
- 21.6%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $5.1B | $1.9B | $1.4B | $1.7B | 23.5% | +9.8% | +37.2% |
Monthly returns
Month-by-month returns of RMD across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $8.2B |
| Current assets | $3.5B |
| Non-current assets | $4.7B |
| Liabilities | $2.2B |
| Current liabilities | $1.0B |
| Non-current liabilities | $1.2B |
| Equity | $6.0B |
| Paid-in capital | $2.0B |
| Retained earnings | $6.1B |
| Treasury stock | $2.1B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; RMD highlighted.
P/E against peers
RMD trades at 20.1x earnings against a peer median of 18.2x (a 11% premium).
Not shown (no positive earnings and no EV / Sales): Centene Corporation, Insmed Incorporated.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| ResMed Inc.RMDthis companyP/E ↑ premium | $28.2B | 20.1x | 4.7x | 23.5% | 14.5x |
| Zoetis Inc.ZTS | $33.3B | 12.5x | 10.0x | 80.2% | 9.9x |
| IQVIA Holdings Inc.IQV | $31.2B | 22.9x | 4.8x | 20.9% | 13.0x |
| Centene CorporationCNC | $31.0B | -4.6x | 1.6x | -33.4% | -6.5x |
| GE HealthCare Technologies Inc.GEHC | $29.0B | 13.9x | 2.8x | 20.1% | 9.2x |
| Biogen Inc.BIIB | $29.0B | 22.4x | 1.6x | 7.1% | 12.5x |
| DexCom, Inc.DXCM | $28.0B | 33.5x | 10.2x | 30.5% | 21.0x |
| Mettler-Toledo International Inc.MTD | $23.9B | 27.4x | — | -3676.8% | 20.9x |
| Insmed IncorporatedINSM | $22.7B | -17.8x | 30.8x | -172.8% | — |
| Peer median | — | 18.2x | 4.8x | 13.6% | 12.5x |
Year-to-date ROI
RMD since 1 January, against earlier years.
Historical volatility
RMD's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 28.0% |
| FY2023 | 27.3% |
| FY2024 | 29.5% |
| FY2025 | 32.8% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $5.1B |
| Cost of revenueCost Of Revenue | $2.1B |
| Gross profitGross Profit | $3.1B |
| Operating expensesOperating Expense | $1.4B |
| Research and developmentResearch And Development | $331.3M |
| Selling, general and administrativeSelling General And Administration | $991.0M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $45.3M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $45.3M |
| Amortization | $45.3M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $45.3M |
| Total expensesTotal Expenses | $3.5B |
| Operating incomeOperating Income | $1.7B |
| Interest and other | |
| Pretax incomePretax Income | $1.7B |
| TaxTax Provision | $276.8M |
| Net incomeNet Income | $1.4B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $8.2B |
| Current assetsCurrent Assets | $3.5B |
| Non-current assetsTotal Non Current Assets | $4.7B |
| LiabilitiesTotal Liabilities Net Minority Interest | $2.2B |
| Current liabilitiesCurrent Liabilities | $1.0B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $1.2B |
| EquityTotal Equity Gross Minority Interest | $6.0B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $1.8B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $1.8B |
| Net income, continuing operationsNet Income From Continuing Operations | $1.4B |
| Depreciation and amortisationDepreciation And Amortization | $235.8M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $235.8M |
| Depreciation | $235.8M |
| Stock-based compensationStock Based Compensation | $91.7M |
| Operating gains and lossesOperating Gains Losses | $6.7M |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $6.7M |
| Change in working capitalChange In Working Capital | $16.7M |
| Other non-cash itemsOther Non Cash Items | — |
| Investing cash flowInvesting Cash Flow | -$200.0M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$200.0M |
| Capital expenditureCapital Expenditure | -$100.6M |
| Purchase of PP&EPurchase Of PPE | -$89.9M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$89.9M |
| AcquisitionsPurchase Of Business | -$139.3M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$139.3M |
| Purchase of investmentsPurchase Of Investment | -$6.4M |
| Sale of investmentsSale Of Investment | $46.3M |
| Net investment purchases and salesNet Investment Purchase And Sale | $39.8M |
| Purchase of intangiblesPurchase Of Intangibles | -$10.8M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$10.8M |
| Financing cash flowFinancing Cash Flow | -$606.3M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$606.3M |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | -$40.0M |
| Net debt issuedNet Issuance Payments Of Debt | -$40.0M |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | -$40.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$40.0M |
| Shares issuedIssuance Of Capital Stock | $74.4M |
| Common stock issuedCommon Stock Issuance | $74.4M |
| Net common stock issuedNet Common Stock Issuance | -$225.6M |
| Common stock repurchasedCommon Stock Payments | -$300.0M |
| Share buybacksRepurchase Of Capital Stock | -$300.0M |
| Dividends paidCash Dividends Paid | -$310.9M |
| Common dividends paidCommon Stock Dividend Paid | -$310.9M |
| Other financing chargesNet Other Financing Charges | -$29.8M |
| Change in cashChanges In Cash | $945.3M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 2,580.0% |
| Cash at the start of the yearBeginning Cash Position | $238.4M |
| Cash at the end of the yearEnd Cash Position | $1.2B |
| Free cash flowFree Cash Flow | $1.7B |
| Supplemental |
Learn while you research
Academy chapters picked for ResMed Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read